Morgan Stanley: CSPC PHARMA (01093) Q3 finished drug sales slightly beat expectations, with multiple pipeline catalysts expected ahead.

date
09:40 20/11/2026
avatar
GMT Eight
Morgan Stanley noted that CSPC PHARMA's finished drug sales grew 10% year-on-year in the third quarter, and the company aims to maintain positive growth in finished drug sales through 2027, with more than 10 innovative drugs in total.
Morgan Stanley issued a research report stating that CSPC PHARMA (01093)'s Q3 finished drug sales slightly beat expectations, with multiple pipeline catalysts ahead that reinforce the firm's investment thesis. The firm maintains its "Overweight" rating on CSPC PHARMA and a target price of HK$12. Morgan Stanley noted that the company targets maintaining positive growth in finished drug sales through 2027, with no price cut for NBP (NBP, national centralized procurement), and Mingfule seeing a price reduction of approximately 9% in the national medical insurance directory, with more than 10 innovative drugs in total. Q3 finished drug sales rose 10% year-on-year and 2.5% quarter-on-quarter, among which central nervous system (CNS) drugs rose 32% year-on-year, oncology drugs fell 23%, anti-infective drugs rose 2%, cardiovascular drugs fell 15%, respiratory drugs fell 15%, digestive drugs rose 41%, and other drugs fell 2%. Q3 business development revenue was RMB373 million, and business development revenue for the first nine months of 2026 was RMB6.3 billion, including partial upfront payments and milestones from the AstraZeneca long-acting peptide platform and the Nectin-4 ADC. Q3 gross margin rose 1 percentage point year-on-year to 67%, the selling and administrative expense ratio for finished drug sales fell 6 percentage points, the R&D ratio was broadly stable at 31%, and Q3 adjusted net profit rose 39% year-on-year. The firm said the next catalysts include Phase III readout for the EGFR ADC in second-line EGFR-mutant non-small cell lung cancer to be presented at the ESMO Asia Congress in early December, as well as early durability data and potential globalization updates for PD-1/IL-15 in 2027.